Highest-materiality recent filing
Closed offering of 3,924,624 common shares at $26.50 and pre-funded warrants for 415,000 shares at $26.499.
Assembly Biosciences expands ABI-6250 into PBC and PSC; Phase 2 basket study planned Q1 2027
ABI-6250, oral NTCP inhibitor, to be studied in PBC and PSC basket Phase 2 starting Q1 2027.
Revenue from Gilead collaboration was $72.3M in 2025 (vs $28.5M in 2024); net loss per share $0.55 (vs $6.69).
Assembly Bio reports Phase 1b data: ABI-1179 98% HSV-2 shedding reduction, ABI-5366 monthly 76%
ABI-1179 50 mg weekly: 98% HSV-2 shedding reduction (p<0.01), exceeds 80-85% target; 91% lesion reduction (p<0.01).
Assembly Biosciences Q3 net loss $9.2M; cash $232.6M; positive Phase 1b data for ABI-5366
Net loss of $9.2M ($0.72 per share) vs $9.6M loss in Q3 2024; revenue from Gilead collaboration $10.8M.
Assembly Bio prices $175M equity financing; net proceeds ~$167M
Underwritten offering: 5.6M shares + 1.04M pre-funded warrants at $19.60/unit; net ~$122M.
Assembly Bio reports 94% reduction in HSV-2 shedding with ABI-5366 350mg weekly in Phase 1b
94% reduction in HSV-2 shedding rate (p<0.01) for 350mg weekly dose vs placebo over 29-day evaluation.
Assembly Bio reports Q2 net loss $10.2M; ABI-6250 shows 4-day half-life supporting once-daily dosing
Net loss $10.2M ($1.33/share) vs $11.2M ($1.98/share) in Q2 2024; revenue from Gilead collaboration $9.6M.
Mean HBV DNA decline of 3.2 log10 IU/mL over 28 days in 400 mg cohort (2.9 logs in 150 mg cohort).
Net loss $40.2M ($6.69/share) narrowed from $61.2M ($13.38/share) in 2023; collaboration revenue $28.5M vs $7.2M.
ABI-1179 had a half-life of ~4 days and high exposure across 50mg-300mg doses, supporting once-weekly oral dosing.
ABI-4334 was well-tolerated with favorable safety profile; no serious adverse events or discontinuations in either cohort.
Assembly Bio receives $10M from Gilead, Gilead buys 940,499 shares at $21.37
Gilead pays $10M upfront payment creditable against future collaboration obligations.
Assembly Bio reports Q3 net loss of $9.6M; positive Phase 1a data for ABI-5366
Net loss of $9.6M ($1.51/share) vs $14.4M ($3.29/share) in Q3 2023; revenue of $6.8M from Gilead collaboration.
ABI-5366 was well-tolerated with favorable safety profile and exposure up to 70 days in healthy participants.
Assembly Biosciences Q2 2024 net loss $11.2M; cash runway into Q1 2026
Cash, equivalents and marketable securities $109.2M as of June 30, 2024, down from $113.0M at March 31, 2024.
Assembly Bio raises $12.6M via equity sales to Armistice & Gilead; cash runway into Q1 2026
Gross proceeds of $12.6M from sale of common stock and warrants to Armistice Capital and Gilead.
Assembly Bio reports Q1 net loss $9.1M; CTAs cleared for two clinical trials
Net loss narrowed to $9.1M ($1.66/sh) from $19.0M ($4.46) YoY; cash $113M funds ops into H2 2025.
Assembly Bio reports FY 2023 net loss of $61.2M; cash of $130.2M; outlines 2024 milestones
Cash, equivalents and marketable securities $130.2M as of Dec 31, 2023, up from $91.6M at end of 2022; funded into H2 2025.
Assembly Biosciences stockholders approve reverse stock split; Board sets ratio at 1-for-12
Stockholders approved a range of 1-for-7 to 1-for-17 reverse stock split; Board selected 1-for-12 ratio.
Assembly Biosciences terminates license agreement with Indiana University for HBV program
On January 11, 2024, Assembly Biosciences notified IURTC of termination of exclusive license for HBV patents including vebicorvir (VBR).
Assembly Biosciences reports Q3 net loss $14.4M; partnership with Gilead provides $100M upfront
Net loss $14.4M ($0.27/sh) vs $23.1M ($0.48/sh) in Q3 2022.
Assembly Biosciences enters $100M collaboration with Gilead; Gilead gets opt-in rights to pipeline
Gilead pays $85M upfront cash and $15M equity ($1.16/share, 13.1M shares) for collaboration.
Assembly Biosciences receives Nasdaq bid-price deficiency notice
Nasdaq notified ASMB that bid price closed below $1.00 for 30 consecutive business days.
Assembly Bio Q2 net loss $16.9M ($0.32/sh); cash $59.8M; ABI-5366 on track for H1 2024 clinic
Net loss $16.9M ($0.32 per share) vs $24.5M ($0.51) in Q2 2022; R&D expense down to $12.5M from $17.8M.
Stockholders reject authorized share increase to 225M at ASMB annual meeting
All eight director nominees elected with no opposition.
Assembly Biosciences Q1 net loss $19M; cash $73M; herpesvirus candidate ABI-5366 advancing to IND
Net loss of $19.0M ($0.37 per share) vs $23.1M ($0.48) in Q1 2022; R&D expenses $14.5M down from $17.2M.
ABI-4334 200 mg QD projected >30x protein-adjusted EC50 for cccDNA; half-life supports once-daily dosing.
Phase 1a for ABI-4334 complete for single-dose and 100mg multiple-dose; half-life supports once-daily dosing; 200mg data expected April.
ABI-5366 is a long-acting HSV-2 helicase inhibitor targeting high-recurrence genital herpes; IND-enabling studies initiated.
Assembly Biosciences reports promising interim results for HBV core inhibitors 3733 and 4334
ABI-H3733 50 mg cohort: 6 of 8 HBV patients reached HBV DNA <LLOQ by day 21; mean 3.1 log decline.
Assembly Biosciences Q3 net loss $23.1M; CEO retirement, new pipeline programs announced
Net loss of $23.1M ($0.48 per share) vs $18.8M ($0.41) in Q3 2021.
Assembly Bio CEO John McHutchison to retire Dec 31; Jason Okazaki to succeed as CEO Jan 1, 2023
John G. McHutchison to retire as CEO effective Dec 31, 2022; remains board member and chair of Science & Technology Committee.
Assembly Biosciences Q2 net loss $24.5M; discontinues vebicorvir, restructures
Cash and securities of $128.6M as of June 30, 2022, projected to fund operations into first half of 2024.
Assembly Bio halts vebicorvir, cuts workforce 30%, CFO exits, extends cash to H1 2024
Discontinues vebicorvir (VBR) based on interim combo study data showing no benefit in viral parameters.
On June 5, 2025, the Board of Directors appointed Jeanette M. Bjorkquist to serve as the Company’s principal financial officer in addition to her role as principal accounting officer.
Ms. Bjorkquist succeeds Jason A. Okazaki, who previously served as both the Company’s principal executive officer and principal financial officer.
On March 13, 2024, the Board appointed Robert D. Cook II, a designee of Gilead Sciences, Inc. ("Gilead"), to serve on the Board.
On December 7, 2023, the Board of Directors (the "Board") of Assembly Biosciences, Inc. (the "Company") appointed Tomas Cihlar, Ph.D., a designee of Gilead Sciences, Inc. ("Gilead"), to serve on the Board.
Jason A. Okazaki, the Company's President and Chief Operating Officer, would succeed Dr. McHutchison as Chief Executive Officer, effective January 1, 2023
John G. McHutchison, A.O., M.D. would retire from his role as Chief Executive Officer effective December 31, 2022
John G. McHutchison, A.O., M.D. will retire from his role as Chief Executive Officer of the Company, effective December 31, 2022.
Michael P. Samar will depart his roles as the Company's Chief Financial Officer, principal financial officer and principal accounting officer effective August 12, 2022.
on July 19, 2022, the Board promoted Mr. Okazaki to President and Chief Operating Officer.
Michael P. Samar, 49, has been promoted to the position of Chief Financial Officer.
Jason A. Okazaki, 45, has been promoted to the position of Chief Operating Officer
On July 19, 2021, the Board of Directors (the “Board”) of Assembly Biosciences, Inc. (the “Company”) appointed Michael Houghton, Ph.D. as an independent, non-employee member of the Board effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event other_material